Previous studies using GITR agonist and PD-1 blockade show marginal synergy between the two antibodies with minimal tumor clearance, therefore, combination with chemotherapy, vaccination or radiation to further prime an immune response was assessed to increase tumor clearance [2, 4, 16]. The gene discussed is TNFRSF18; the disease is neoplasm.